Despite few studies on intracellular heat shock protein70, the clinical association between insulin resistance and extracellular heat shock protein70 (eHSP70) is not well studied. In the current study, we examined the association between homeostatic model assessment-insulin resistance (HOMA-IR) and eHSP70 in patients with type 2 diabetes (T2DM) and healthy controls. A total of 145 patients with T2DM and 41 matched healthy controls were selected. Patients and controls were divided based on waist circumference (WC) to two groups, and eHSP70 was compared between them. The association between HOMA-IR and eHSP70 was examined using regression models adjusted for age, high-sensitive C-reactive protein (hs-CRP), and central obesity as confounding factors. While eHSP70 and hs-CRP were significantly correlated with HOMA-IR in patients with T2DM (p = 0.032, 0.025, respectively), there was no correlation between eHSP70 and HOMA-IR in the control group. Extracellular HSP70 and hs-CRP were not correlated in healthy controls. But a significant association appeared between eHSP70 and hs-CRP in patients with T2DM (p = 0.05). Both BMI and WC were not correlated with eHSP70 in both groups. Extracellular HSP70 was positively associated with HOMA-IR in patients with T2DM, independent from hs-CRP and obesity. We also showed eHSP70 levels remained unchanged through increase in BMI or WC in patients with T2D and in healthy controls. Our findings suggest that eHSP70 may contribute to the pathogenesis of T2DM by increasing insulin resistance.
Introduction
Insulin resistance is one of the major components of type 2 diabetes (T2DM) characterized by decreased tissue response to serum insulin (Gerich 2000) . Insulin resistance and inflammation are correlated, as has been already documented by to increase in inflammation, especially in obese people (Chen and Chen 2015; Chen et al. 2017) . In fact, it has been postulated that adipocytes, especially in visceral fat contribute to insulin resistance by producing cytokines, which provide an inflammatory media in the body (Mayer and Bukau 2005; Nakhjavani et al. 2010) . It is believed that the abdominal obesity is the fundamental culprit for insulin resistance and its associated abnormalities (Fontana et al. 2007; Bruun et al. 2005) .
HSP70 is a family of a larger group of proteins collectively called as heat shock proteins, which their expression is induced by chemical and physical stress. In cells, they are believed to maintain the native folding of proteins in stress conditions (Mayer and Bukau 2005) . Increased extracellular HSP70 (eHSP70) has been reported in chronic inflammatory diseases, such as T2DM and rheumatoid arthritis (Nakhjavani et al. 2010; Najafizadeh et al. 2015) . Data concerning the role of HSP70 in insulin resistance is mostly limited to works on intracellular HSP70 (iHSP70) (Ohno et al. 2010; Sawa et al. 1996; Yaglom et al. 1999 ). While iHSP70 is believed to protect against insulin resistance by blocking c-Jun N-terminal kinase (JNKs) and thus reverse the cycle that leads to T2DM (Ohno et al. 2010; Park et al. 2001; Chung et al. 2008; Hooper and Hooper 2009) , the role of eHSP70 in insulin resistance is not well-studied.
There are studies on patients with T2DM and elderly patients indicating that serum HSP70 levels are positively associated with inflammatory parameters, such as CRP (Njemini et al. 2004; Nakhjavani et al. 2013) . Therefore, it might be hypothesized that inflammatory conditions, such as T2DM and insulin resistance, could trigger a rise in eHSP70. In this study first, we investigated the relationship between eHSP70 and insulin resistance in patients with T2DM and healthy controls stratified into obese and non-obese groups. Then, we questioned whether the correlation between eHSP70 and insulin resistance is independent or it is just a consequence of the inflammatory state in T2DM by adjusting for hs-CRP and obesity.
Material and methods

Study population
This is a cross-sectional study conducted in diabetes clinic of Vali-asr Hospital affiliated with Tehran University of Medical Sciences. We selected 145 patients with T2DM. The diagnosis of diabetes was made based on American Diabetes Association 2015 (Diabetes Care 2015). Exclusion criteria were smoking, pregnancy, proteinuria, renal involvement (creatinine > 1.5 mg/dl or GFR < 70 cc/min), glomerulonephritis, congestive heart failure, insulin therapy, and hospital admission in recent months. None of the participants had any overt diabetic complication. Forty-one healthy participants were selected among the volunteered healthy staff of the hospital as the control group. Before enrollment, written informed consents were taken from all participants. The ethics committee of the Tehran University of Medical Sciences approved the study protocol.
Clinical and laboratory measurements
Demographic and anthropometric characteristics, including age, medication, weight, height, and the waist circumference (WC), were obtained from the participants through the interview and baseline measurements. Body mass index (BMI) was computed as weight in kilograms divided by height per square meter (kg/m 2 ). After 12 h of fasting, venous blood samples were collected for the biochemical analysis. Fasting blood glucose and 1 h post-prandial glucose were measured by the glucose oxidase method. Measurement of serum creatinine was performed by Jaffe method. Plasma total cholesterol, triglyceride, highdensity lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were determined using direct enzymatic method (Parsazmun, Karaj, Iran). Serum HSP70 was measured using a quantitative sandwich ELISA immunoassay (EKS-715, Stressgen, USA). The intra-and inter-assay CVs ranged between 4.5 and 7%. Insulin was measured by radioimmunoassay (Immunotech, Prague, Czech Republic). Sensitivity was 0.5 μU/mL, and the upper limits of intraand inter-assay coefficients of variation were 4.3 and 3.4, respectively. hs-CRP was assessed using a two-site ELISA (CAN-CRP-4360, Diagnostic Biochem). Intra-and interassay CV were 5-15.2% and 7.8-9.9%, respectively.
Outcome definitions
The primary outcome of the current study was insulin resistance. Insulin resistance was determined using HOMA-IR. HOMA-IR was calculated by following equation: fasting insulin (U/l) × fasting glucose (mg/dl) / 405.
Central obesity was defined as (WC > 102 for men and WC > 88 for women).
Statistical analysis
Continuous variables were summarized as mean (SD) if were normally distributed and median (interquartile range) otherwise. Also, categorical variables were reported as number (percentage). Before comparing variables, the best transformation for each non-normally distributed parameter assessed by Shapiro-Wilk test. Continuous variables among groups were examined using a one-way analysis of variance (ANOVA) and independent sample t test. Comparisons of HSP70, hs-CRP (both logarithmically transformed), and HOMA-IR (transformed by root squaring) among four groups of subjects based on T2DM (control and patients with T2DM) and BMI (categorized into obese (BMI > 30) and none-obese (BMI < 30)) were done using regression models adjusted for age. The association between eHSP70 and HOMA-IR was examined in four different regression models. The model 1 was adjusted for age and metformin therapy; the model 2 was further adjusted for central obesity; in model 3, we selected age and hs-CRP as covariates, and the model 4 was adjusted for age, central obesity, and hs-CRP. Correlations among eHSP70, BMI, WC, HOMA-IR, and hs-CRP were examined using Pearson correlation.
Results
Baseline characteristics
We had 145 patients with T2DM (70 obese, 85 non-obese patients) (mean age 54.5) and 41 healthy controls (19 obese, 22 non-obese patients) (mean age 52.7). Fourteen of them were on metformin monotherapy, 43 on glibenclamide, and 74 were on combination therapy of metformin and glibenclamide.
Percentage of females, WC, hs-CRP, and BMI were significantly higher in obese patients with T2DM compared to nonobese patients. FHDL-C was less in obese controls compared to non-obese subjects, while TG, FBS, BMI, WC, weight, and percentage of female were higher. FBS, TG, hs-CRP, HOMA-IR, insulin, and eHSP70 were significantly higher in patients with diabetes compared to healthy control (Table 1) . Extracellular HSP70, hs-CRP, and HOMA-IR were significantly different between patients with diabetes and healthy control groups after adjustment for age (p = 0.001, p < 0.001, and p = 0.001, respectively).
There was no significant difference in eHSP70 and HOMA-IR between obese and non-obese participants in both patients and control groups after adjustment for age (all p > 0.05). However, hs-CRP differed in obese and non-obese people in patients with T2DM (Fig. 1) .
Correlations
We studied the correlations between eHSP70, hs-CRP, and HOMA-IR (transformed by squared root). While eHSP70 and hs-CRP were significantly correlated with HOMA-IR in Creatinine (mg/dL) 0.9 ± 0.1 1 ± 0.2 0.9 ± 0.2 1 ± 0.4 HOMA-IR 3 ± 1 5.9 ± 7.4 8.7 ± 8.5# 7.4 ± 5.3
hs-CRP (mg/L) 1.6 ± 1.2 2.5 ± 1.9 9.5 ± 16.2# 16.7 ± 26.4#* Insulin (mIU/L) 14.6 ± 4.7 26.4 ± 31.7 17.5 ± 13.4 16.4 ± 11.3# HSP70 (ng/mL) 0.3(0.1-2) 0.5(0.1-2) 0.6(0.3-1)# 0.6(0.2-1) *Show a significant difference between obese and lean subjects in control and T2DM groups separately (p < 0.05) #Shows a significant difference between T2DM patients and healthy subjects in lean and obese group separately Central obesity is defined by WC > 102 cm or 88 cm for men and women, respectively. FBS: fasting blood sugar, LDL-C: low-density lipoprotein-cholesterol, HDL-C: high-density lipoprotein-cholesterol, HOMA-IR, homeostatic model assessment-insulin resistance, hs-CRP: high sensitivity C-reactive protein, HSP70: heat shock protein 70, T2DM: type 2 diabetes patients with T2DM (p = 0.032, 0.025, respectively), there was no correlation between eHSP70 and HOMA-IR in the control group (Fig. 2) . Extracellular HSP70 and hs-CRP were not correlated in healthy controls. But a significant association appeared between eHSP70 and hs-CRP in patients with T2DM (p = 0.05). BMI and WC were not correlated with eHSP70 in both groups, but they were both associated with hs-CRP (p < 0.05) ( Table 2) . We studied the association between eHSP70 and HOMA-IR in four models. According to all models, this association was significant after adjustment for age, metformin therapy, central obesity, and hs-CRP (p = 0.026) ( Table 3 ).
Discussion
Despite several experimental studies on iHSP70, there are very few data on serum eHSP70 and its clinical association with insulin resistance. In the current study, we examined this association in patients with T2DM and also in healthy controls. We demonstrated that elevated serum HSP70 levels in patients with T2DM are associated with increased HOMA-IR. Fig. 1 Comparison of HSP70, hs-CRP (both logarithmically transformed), and HOMA-IR (transformed by squared root) among the control group and patients with T2DM, categorized into central obese (WC > 102 cm or 88 cm for men and women, respectively) and lean are illustrated in b and c, respectively. Although patients with T2DM generally had a significant difference with the control group in HSP70 and HOMA-IR, obesity did not make any change in these two groups. However, hs-CRP differed both between control and T2DM groups and also in obese and non-obese people in patients with T2DM. Comparison was done using regression models adjusted for age. * and ** show significance difference at the level of p < 0.05 and p < 0.01, respectively Fig. 2 Relationship between HSP70, hs-CRP, and HOMA-IR. Studies have already shown a correlation between HSP70 and inflammation along with a correlation between inflammation and insulin resistance, using hs-CRP and HOMA-IR as markers for inflammation and insulin resistance, respectively. Although rationally an association of HSP70 and insulin resistance might also be deduced, here, we have demonstrated an association between extracellular HSP70 with HOMA-IR even by adjustment for hs-CRP. This fact suggests a non-inflammatory role for extracellular HSP70 in driving insulin resistance Interestingly, this association remained significant after adjustment for hs-CRP and obesity. The results did not show any association between eHSP70 and HOMA-IR in the control group. We also found out that eHSP70 was higher in patients with T2DM compared to healthy subjects.
A number of studies show a dual behavior of HSP70 based on its location. It is reported that iHSP70 expressed in muscle tissues are protective against insulin resistance development (Chichester et al. 2015) . On the other hand increased serum eHSP70 (eHSP70) has been reported in chronic diseases such as rheumatoid arthritis and T2DM (Najafizadeh et al. 2015; Dulin et al. 2010 ). As we have shown earlier, eHSP70 is positively associated with T2DM and also its duration (Nakhjavani et al. 2010) . There are two studies examining the association between insulin resistance and eHSP70 only in healthy subjects. To the best of our knowledge, there are no studies focusing on the association of insulin resistance and eHSP70 in patients with T2DM. Krause et al. have indicated that eHSP70 may mediate β cell failure, and it is positively associated with insulin resistance in non-diabetic elderly people (Krause et al. 2014 ). In another study, an inverse relation between HOMA-IR and serum HSP70 has been reported in 50 healthy African American subjects with no major known disease (Islam et al. 2014) . Here, we have demonstrated the appearance of an independent positive association between serum HSP70 and insulin resistance in patients with T2DM.
In order to find out if HSP70 has an independent role in incident insulin resistance or it only reflects the inflammatory state, we adjusted the association between HOMA-IR and eHSP70 for hs-CRP and central obesity, which still remained significant. It is believed that visceral adiposity is the more important contributing factor to the insulin resistance rather than general obesity (Bruun et al. 2005) . This is why we decided to use WC instead of BMI for defining obesity.
The impact of medication especially metformin on insulin resistance is well known (Diabetes Care 2013). Metformin All models also were adjusted for the age. HOMA-IR is transformed by root squaring. HOMA-IR, homeostatic model assessment-insulin resistance, hs-CRP: high sensitivity increases peripheral insulin sensitivity by the activation of AMP-activated protein kinase alpha2 (Musi et al. 2002) . Therefore, it can be postulated that metformin therapy can biased the results. For this reason, we considered medication in all the models and interestingly, the association between eHSP70 and insulin resistance remained significant. It is assumed that eHSP70 mediates activation of JNKs by Toll-like receptors, which leads to phosphorylation of Insulin receptor substrate-1 (IRS-1) at Ser307 in rodents or Ser312 in human and consequently reduced glucose uptake in sensitive tissues or simply put insulin resistance (Krause et al. 2014; Lee et al. 2003; Aguirre et al. 2002) . In this study, there was no significant difference in eHSP70 between obese and non-obese participants in both diabetic and control groups. Moreover, we did not observe any significant association between BMI or WC and eHSP70. Though obese patients are characterized by systematic and adipose low-grade inflammation (Hotamisligil et al. 1995) , even lean patients with T2DM have shown increased inflammatory markers (Prattichizzo et al. 2018) . It suggests other sources of inflammation and cell stress exist beyond adipose tissues. In our setting, the absence of correlation between BMI and eHSP70 implies that origin of increased circulating HSP70 is not only the fat tissue. Present literature concerning the association between obesity and eHSP70 is controversial. Mardan-Nika et al. have already shown the significant association of HSP70 gene polymorphism with obesity in Iranian population (Mardan-Nik et al. 2016) . Also, Rodrigues-Krause et al. have demonstrated that eHSP70 levels are higher in obese patients with T2DM compared to non-obese patients by measuring eHSP70 in seven patients with T2DM and eight healthy controls (Rodrigues- Krause et al. 2012 ). On the other hand, Islam et al. study reported that HSP70 levels decrease as BMI and WC increase in healthy African American subjects (Islam et al. 2014) .
We found an adjusted positive association between eHSP70 and hs-CRP in the patient with T2DM. Interestingly, we did not observe any correlation between hs-CRP and eHSP70 in healthy control subjects. It is believed that the effect of eHSP70 on cells is mainly due to proinflammatory pathways. It has been shown that in vitro stimulation of rat splenocytes and macrophages with eHSP70 results in production and release of nitric oxide (NO) and proinflammatory cytokines, such as tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β) (Campisi et al. 2003) . The appearance of pathological correlations between leptin and eHSP70 and also between asymmetric dimethylarginine and eHSP70 in inflammatory conditions, such as T2DM (Nakhjavani et al. 2013; Nakhjavani et al. 2012) , has been reported in previous studies. Extracellular HSP70 could activate pro-inflammatory pathways by binding to TLR-2 and TLR-4 (Vabulas et al. 2002) . We postulate that T2DM may provide an inflammatory environment (Wang et al. 2013) and upregulate this reaction.
There are some limitations in our study to note. First, this is a cross-sectional study, and prospective studies are needed to confirm and improve the present results. Second, we did not have data on nutrition habits and physical activity of the participants, which may influence insulin resistance and obesity. Third, we did not have facilities to assess body fat or body composition, so the definite association between adiposity and eHSP70 needs further research. Forth, obese and lean diabetics showed no statistically significant difference in HOMA in our study. This finding may cause some misleading in our study and needs clarification. We have postulated that longer duration of diabetes in lean T2DM patients (with a trend to significance p = 0.08) might propel their HOMA-IR toward obese subjects. It is established that longer duration of disease is associated with decrease in beta cell function and insulin secretion (Rahier et al. 2008) . Therefore, it can result in lower HOMA-IR due the same FBS measures in our study participants. Nevertheless, the strength of our study was the relatively large sample size and the similarity in groups in most of the confounding clinical and laboratory parameters.
In conclusion, we have demonstrated that there is an independent positive association between eHSP70 and HOMA-IR in patients with T2DM. We also have shown that eHSP70 is not associated with BMI in patients with T2DM and also in healthy subjects. Our findings suggest that eHSP70 may contribute to the pathogenesis of T2DM by increasing insulin resistance. Further studies are recommended to assess the potential use of HSP70 in prediction and treatment of T2DM.
